These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 27494299

  • 1. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.
    Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B.
    Amyloid; 2016 Sep; 23(3):178-183. PubMed ID: 27494299
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy.
    Amass L, Li H, Gundapaneni BK, Schwartz JH, Keohane DJ.
    Orphanet J Rare Dis; 2018 Dec 17; 13(1):225. PubMed ID: 30558645
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study.
    Planté-Bordeneuve V, Gorram F, Salhi H, Nordine T, Ayache SS, Le Corvoisier P, Azoulay D, Feray C, Damy T, Lefaucheur JP.
    J Neurol; 2017 Feb 17; 264(2):268-276. PubMed ID: 27878441
    [Abstract] [Full Text] [Related]

  • 7. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years.
    Barroso FA, Judge DP, Ebede B, Li H, Stewart M, Amass L, Sultan MB.
    Amyloid; 2017 Sep 17; 24(3):194-204. PubMed ID: 28758793
    [Abstract] [Full Text] [Related]

  • 8. Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy.
    Gundapaneni BK, Sultan MB, Keohane DJ, Schwartz JH.
    Eur J Neurol; 2018 Mar 17; 25(3):464-468. PubMed ID: 29115008
    [Abstract] [Full Text] [Related]

  • 9. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
    Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceição IM, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Wilson A, Grogan DR.
    Neurology; 2012 Aug 21; 79(8):785-92. PubMed ID: 22843282
    [Abstract] [Full Text] [Related]

  • 10. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
    Lamb YN, Deeks ED.
    Drugs; 2019 Jun 21; 79(8):863-874. PubMed ID: 31098895
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
    Cortese A, Vita G, Luigetti M, Russo M, Bisogni G, Sabatelli M, Manganelli F, Santoro L, Cavallaro T, Fabrizi GM, Schenone A, Grandis M, Gemelli C, Mauro A, Pradotto LG, Gentile L, Stancanelli C, Lozza A, Perlini S, Piscosquito G, Calabrese D, Mazzeo A, Obici L, Pareyson D.
    J Neurol; 2016 May 21; 263(5):916-924. PubMed ID: 26984605
    [Abstract] [Full Text] [Related]

  • 13. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
    Maurer MS, Elliott P, Merlini G, Shah SJ, Cruz MW, Flynn A, Gundapaneni B, Hahn C, Riley S, Schwartz J, Sultan MB, Rapezzi C, ATTR-ACT Study Investigators.
    Circ Heart Fail; 2017 Jun 21; 10(6):. PubMed ID: 28611125
    [Abstract] [Full Text] [Related]

  • 14. [Treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a case report].
    Miyazaki Y.
    Nihon Ronen Igakkai Zasshi; 2017 Jun 21; 54(1):75-80. PubMed ID: 28202889
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Planté-Bordeneuve V, Lin H, Gollob J, Agarwal S, Betts M, Fahrbach K, Chitnis M, Polydefkis M.
    Expert Opin Pharmacother; 2019 Mar 21; 20(4):473-481. PubMed ID: 30489166
    [Abstract] [Full Text] [Related]

  • 17. A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy.
    Huber P, Flynn A, Sultan MB, Li H, Rill D, Ebede B, Gundapaneni B, Schwartz JH.
    Amyloid; 2019 Dec 21; 26(4):203-209. PubMed ID: 31353964
    [Abstract] [Full Text] [Related]

  • 18. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM.
    Drugs Today (Barc); 2019 Dec 21; 55(12):727-734. PubMed ID: 31942875
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tafamidis for transthyretin amyloidosis.
    de Lartigue J.
    Drugs Today (Barc); 2012 May 21; 48(5):331-7. PubMed ID: 22645721
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.